Theratechnologies Inc THTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if THTX is a good fit for your portfolio.
News
-
Theratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of Shareholders
-
Theratechnologies to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
-
Theratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024
-
Theratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology™ Oncology Platform
-
Theratechnologies Appoints Elina Tea to its Board of Directors
-
Theratechnologies to Announce First Quarter 2024 Financial Results and Provide Business Update
-
Theratechnologies to Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology™ Platform
-
Theratechnologies Announces Update on its Preclinical Oncology Research Program
Trading Information
- Previous Close Price
- $1.36
- Day Range
- $1.30–1.35
- 52-Week Range
- $0.88–4.30
- Bid/Ask
- $1.30 / $1.50
- Market Cap
- $59.77 Mil
- Volume/Avg
- 20,748 / 33,551
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.42
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States. It generates revenue from one customer RxCrossroads, which is domiciled in the United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 103
- Website
- https://www.theratech.com
Comparables
Valuation
Metric
|
THTX
|
PNT
|
CRNX
|
---|---|---|---|
Price/Earnings (Normalized) | — | 11.36 | — |
Price/Book Value | — | 3.12 | 5.59 |
Price/Sales | 0.42 | 5.50 | 639.90 |
Price/Cash Flow | — | 13.90 | — |
Price/Earnings
THTX
PNT
CRNX
Financial Strength
Metric
|
THTX
|
PNT
|
CRNX
|
---|---|---|---|
Quick Ratio | 1.14 | 9.01 | 12.92 |
Current Ratio | 1.34 | 9.14 | 13.07 |
Interest Coverage | −1.35 | — | — |
Quick Ratio
THTX
PNT
CRNX
Profitability
Metric
|
THTX
|
PNT
|
CRNX
|
---|---|---|---|
Return on Assets (Normalized) | −24.85% | 20.67% | −38.81% |
Return on Equity (Normalized) | — | 23.56% | −44.79% |
Return on Invested Capital (Normalized) | −36.78% | 23.38% | −45.62% |
Return on Assets
THTX
PNT
CRNX
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Hczfbdzyx | Khlh | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Mbcrwsgbp | Byxbhj | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Jgbcwys | Xglwx | $97.8 Bil | |
MRNA
| Moderna Inc | Nvvxydpk | Mvqc | $38.8 Bil | |
ARGX
| argenx SE ADR | Bjrjply | Flgbx | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Pxsqfdqx | Frszb | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Tmjlbywf | Qvjnf | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Csvsjwnm | Nxflvx | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Hlkflwrqk | Yzdfbfm | $12.5 Bil | |
INCY
| Incyte Corp | Kdybwcxp | Jjfhr | $11.5 Bil |